Go to main contents Go to main menus

News Room

contents area

Press Release

Open sns share
Close sns share
프린트하기

detail content area

A Temperature-Responsive Nanoparticle Vaccine Improves Protection Against Mycobacterium tuberculosis
  • Date2025-06-05 18:39
  • Update2025-06-05 18:39
  • DivisionDivision of Infectious Disease Vaccine Research
  • Tel043-913-4205

A Temperature-Responsive Nanoparticle Vaccine Improves Protection Against Mycobacterium tuberculosis


- KDCA National Institute of Health (NIH) and Korea Institute of Ceramic Engineering and Technology (KIET) announced joint research achievement


Osong, 05 June 2025 ━ The Korea Disease Control and Prevention Agency (KDCA) has announced the results of research showing that the application of a novel temperature-responsive particle—a new vaccine delivery system—to a vaccine for tuberculosis enhanced immune responses and demonstrated protective efficacy against Mycobacterium tuberculosis infection.


※ Paper Title: A temperature-responsive PLA-based nanosponge as a novel nanoadjuvant and efficient carrier of Ag85B for effective vaccine against Mycobacterium tuberculosis (Published in Cell Communication and Signaling, see attachment for reference)


This research is a collaborative achievement combining the temperature-responsive nanoparticle technology developed by Korea Institute of Ceramic Engineering and Technology (KIET) and the tuberculosis vaccine development technology from the National Institute of Health (NIH).

The nanoparticle applied in this study is a novel concept* that exists in particle form at room temperature and releases the antigen at body temperature. This design allows the antigen to be released gradually, activating long-term immune responses, and enables long-term storage at room temperature without the need for additional additives.

* A Temperature-Responsive Nanosponge (aPNS): Composed of FDA-approved Polylactic acid and Pluronic F127.

When applied to the tuberculosis vaccine, the nanoparticle enhanced T-cell immune activation, providing better protective effects against Mycobacterium tuberculosis infection compared to traditional BCG vaccines or antigen-only administration.

Based on these results, the research team plans to expand collaborative studies applying this new nano delivery system technology to various vaccine platforms, including recombinant protein vaccines and mRNA vaccines.


external_image



Figure Deion: The administration of the recombinant protein nano vaccine increases the production of antigen-specific immunoglobulins and inhibits airborne Mycobacterium tuberculosis infection. Additionally, there is an increase in antigen-specific immunoglobulins, T cell immune response and the production of pro-inflammatory cytokines and chemokines.


<Figure 1> A Diagram of Tuberculosis Vaccine Research Using Nanoparticle Delivery System


Dokeun Kim, Director of the Center for Vaccine Research, stated, “In addition to the delivery system, we will continue to focus on ongoing research in elementary vaccine technologies such as adjuvant, platforms, and antigen optimization, in order to secure essential vaccine technologies based on domestic capabilities, preparing and responding to emerging and variant infectious diseases.
Files
This public work may be used under the terms of the public interest source This public work may be used under the terms of the public interest source
Prev. Next.
TOP